JP7250764B2 - Ｔｇ０２の多形形態 - Google Patents

Ｔｇ０２の多形形態 Download PDF

Info

Publication number
JP7250764B2
JP7250764B2 JP2020508985A JP2020508985A JP7250764B2 JP 7250764 B2 JP7250764 B2 JP 7250764B2 JP 2020508985 A JP2020508985 A JP 2020508985A JP 2020508985 A JP2020508985 A JP 2020508985A JP 7250764 B2 JP7250764 B2 JP 7250764B2
Authority
JP
Japan
Prior art keywords
cancer
patient
citrate
administered
polymorphic form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020508985A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531463A (ja
JP2020531463A5 (https=
Inventor
ロバート ケイ． マンスフィールド
トレイシー パロット
Original Assignee
コセラ バイオサイエンス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コセラ バイオサイエンス， インコーポレイテッド filed Critical コセラ バイオサイエンス， インコーポレイテッド
Publication of JP2020531463A publication Critical patent/JP2020531463A/ja
Publication of JP2020531463A5 publication Critical patent/JP2020531463A5/ja
Application granted granted Critical
Publication of JP7250764B2 publication Critical patent/JP7250764B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020508985A 2017-08-18 2018-08-17 Ｔｇ０２の多形形態 Active JP7250764B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762547157P 2017-08-18 2017-08-18
US62/547,157 2017-08-18
PCT/US2018/000264 WO2019035985A1 (en) 2017-08-18 2018-08-17 POLYMORPHIC FORM OF TG02

Publications (3)

Publication Number Publication Date
JP2020531463A JP2020531463A (ja) 2020-11-05
JP2020531463A5 JP2020531463A5 (https=) 2021-09-30
JP7250764B2 true JP7250764B2 (ja) 2023-04-03

Family

ID=65359869

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020508985A Active JP7250764B2 (ja) 2017-08-18 2018-08-17 Ｔｇ０２の多形形態

Country Status (14)

Country Link
US (4) US10544162B2 (https=)
EP (2) EP4364741A3 (https=)
JP (1) JP7250764B2 (https=)
KR (1) KR102758037B1 (https=)
CN (1) CN111372934B (https=)
AU (1) AU2018317865B2 (https=)
CA (1) CA3073270A1 (https=)
ES (1) ES2977589T3 (https=)
IL (1) IL272697B2 (https=)
MX (1) MX2020001875A (https=)
RU (1) RU2020111019A (https=)
SG (1) SG11202001441WA (https=)
TW (1) TWI785098B (https=)
WO (1) WO2019035985A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201808306PA (en) 2016-03-24 2018-10-30 Tragara Pharmaceuticals Inc Treatment of cancer with tg02
RU2020111019A (ru) 2017-08-18 2021-09-20 Трагара Фармасьютикалз, Инк. Полиморфная форма tg02
JP7684910B2 (ja) * 2019-04-22 2025-05-28 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 小児対象において神経膠腫を治療するためのｔｇ０２の使用
CN110664760B (zh) * 2019-10-28 2020-10-23 浙江大学 一种负载vegfr靶向抑制剂的药物载体及其制备方法和应用
WO2024031406A1 (en) * 2022-08-10 2024-02-15 Xiang Li Idh mutations as biomarkers for zotiraciclib therapy
CN115429793A (zh) * 2022-08-15 2022-12-06 复旦大学附属中山医院 一种化合物在制备治疗肝细胞癌药物中的应用
CN115305251B (zh) * 2022-08-30 2023-06-27 中国农业科学院北京畜牧兽医研究所 Ap2-mybl2分子模块在调控原花色素生物合成中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130150378A1 (en) 2010-02-05 2013-06-13 Robert K. Mansfield Solid state forms of macrocyclic kinase inhibitors

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL63907A0 (en) 1980-09-24 1981-12-31 Cetus Corp Diagnostic method and antibody probe for use therein
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
ATE53862T1 (de) 1982-01-22 1990-06-15 Cetus Corp Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel.
US4683194A (en) 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
WO2003070887A2 (en) 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
SI1853250T1 (sl) 2005-02-18 2012-01-31 Abraxis Bioscience Llc Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
NZ568325A (en) 2005-11-16 2011-05-27 S Bio Pte Ltd Macrocyclic oxygen linked pyrimidine derivatives
KR101511074B1 (ko) 2007-04-16 2015-04-13 애브비 인코포레이티드 7-치환된 인돌 Ｍｃｌ-1 억제제
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
GB0806652D0 (en) 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CN102203132A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
EP2418955A4 (en) * 2009-04-15 2012-11-21 Poniard Pharmaceuticals Inc ORAL PICOPLATIN ANTITUMOR THERAPY WITH HIGH BIOAVAILABILITY
JP4965623B2 (ja) 2009-09-30 2012-07-04 インターナショナル・ビジネス・マシーンズ・コーポレーション 所定のソフトウェアの実行パラメータを入力フィールドへ入力することを支援するための方法、システム、およびプログラム
WO2011103016A2 (en) 2010-02-19 2011-08-25 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
US9801853B2 (en) 2010-04-06 2017-10-31 Fred Hutchinson Cancer Research Center Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of MYC-driven tumor cells
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
WO2013043569A1 (en) 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
CA2850570A1 (en) 2011-09-30 2013-04-04 Glaxosmithkline Llc Methods of treating cancer
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
EP3536314A1 (en) 2012-03-12 2019-09-11 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
CN113967253A (zh) 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CA2916638C (en) 2012-07-31 2021-01-12 The Brigham And Women's Hospital, Inc. Modulation of the immune response
KR20230156450A (ko) 2012-10-15 2023-11-14 에피자임, 인코포레이티드 암을 치료하는 방법
SI2958916T1 (sl) 2013-02-21 2018-11-30 Pfizer Inc. Trdne oblike selektivnih zaviralcev CDK4/6
EA037554B1 (ru) 2013-03-15 2021-04-13 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Анти-lag-3 связывающие белки
NZ718821A (en) 2013-09-11 2022-07-01 Medimmune Ltd Anti-b7-h1 antibodies for treating tumors
EP3113798B1 (en) 2014-03-07 2019-06-05 University Health Network Methods and compositions for modifying the immune response
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
KR20240010105A (ko) 2014-03-14 2024-01-23 아지오스 파마슈티컬스 아이엔씨. 치료적으로 활성인 화합물의 약제학적 조성물
SG11201808306PA (en) 2016-03-24 2018-10-30 Tragara Pharmaceuticals Inc Treatment of cancer with tg02
RU2020111019A (ru) 2017-08-18 2021-09-20 Трагара Фармасьютикалз, Инк. Полиморфная форма tg02

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130150378A1 (en) 2010-02-05 2013-06-13 Robert K. Mansfield Solid state forms of macrocyclic kinase inhibitors

Also Published As

Publication number Publication date
RU2020111019A3 (https=) 2022-03-18
SG11202001441WA (en) 2020-03-30
JP2020531463A (ja) 2020-11-05
EP3668876A1 (en) 2020-06-24
EP3668876A4 (en) 2021-04-28
TWI785098B (zh) 2022-12-01
US20190055263A1 (en) 2019-02-21
EP4364741A2 (en) 2024-05-08
AU2018317865A1 (en) 2020-03-19
CN111372934B (zh) 2024-04-26
US20240254141A1 (en) 2024-08-01
KR20200078481A (ko) 2020-07-01
IL272697B2 (en) 2023-12-01
EP3668876B1 (en) 2024-01-24
IL272697A (en) 2020-04-30
CN111372934A (zh) 2020-07-03
ES2977589T3 (es) 2024-08-27
MX2020001875A (es) 2020-07-29
CA3073270A1 (en) 2019-02-21
US20200262843A1 (en) 2020-08-20
AU2018317865B2 (en) 2023-03-16
US10544162B2 (en) 2020-01-28
RU2020111019A (ru) 2021-09-20
WO2019035985A1 (en) 2019-02-21
US12043630B2 (en) 2024-07-23
IL272697B1 (en) 2023-08-01
US20240254142A1 (en) 2024-08-01
TW201920199A (zh) 2019-06-01
KR102758037B1 (ko) 2025-01-22
EP4364741A3 (en) 2024-07-03

Similar Documents

Publication Publication Date Title
JP7250764B2 (ja) Ｔｇ０２の多形形態
CN114269715A (zh) 作为氨基酸转运抑制剂的二苄基胺
JP7026299B2 (ja) Ｔｇ０２によるがん治療
JP2022536419A (ja) アミノ酸輸送阻害剤及びその使用
EP3515892B1 (en) Compounds and methods for ido and tdo modulation, and indications therefor
HUE024426T2 (en) Imidazo [4,5-c] quinolin-2-one and its use as P13 kinase / mTOR double inhibitor
JP7574198B2 (ja) Ｄｏｎプロドラッグおよび免疫チェックポイント阻害剤による組み合わせ治療法
US20240174658A1 (en) Heteroaromatic Inhibitors of Cancer Metabolism
HK40030306A (en) Polymorphic form of tg02
WO2022232565A1 (en) Prodrugs of 6-diazo-5-oxo-l-norleucine
WO2023069644A1 (en) Compounds useful in modulating egfr and pi3k
HK40030306B (zh) Tg02的多晶型形式
RU2806857C2 (ru) Соединения, фармацевтические композиции, способы приготовления соединений и их применение в качестве ингибиторов киназы atr
WO2022140661A1 (en) Combination therapy with a vinca alkaloid n-oxide and an immune checkpoint inhibitor
WO2022261117A1 (en) Combination therapy with a don prodrug and a tigit inhibitor
HK1188454B (en) Imidazo [4, 5 -c]quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor
NZ611541B2 (en) Imidazo[4,5-c]quinolin-2-one compound and its use as pi3 kinase / mtor dual inhibitor

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210817

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220119

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221026

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230322

R150 Certificate of patent or registration of utility model

Ref document number: 7250764

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250